Prompt Approval of Safe Generic Drugs Act
Prompt Approval of Safe Generic Drugs Act
Plain Language Summary
# Summary of HR 843: Prompt Approval of Safe Generic Drugs Act **What the bill does:** This bill would allow the FDA to approve generic drug applications even when the drug's label is missing certain safety information that is protected by another company's patent or exclusivity rights. Currently, generic drugs must have labeling identical to the original brand-name drug, which can delay approval if safety information is patented by the original manufacturer. This bill would remove that barrier, allowing generic versions to be approved and sold without that patent-protected information on the label. **Who it affects:** This primarily benefits generic drug manufacturers and patients who use generic medications. Generic drugs are typically cheaper than brand-name drugs, so easier approval could lower costs and increase access.
The bill could also affect brand-name pharmaceutical companies that hold patents on safety information. The change could potentially impact how drug safety information is communicated to patients and doctors. **Current status:** The bill is currently in committee and has not yet been voted on by the full House of Representatives. It was introduced by Representative Nanette Barragán (D-CA) in the 119th Congress.
CRS Official Summary
Prompt Approval of Safe Generic Drugs ActThis bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a generic drug despite the omission of certain safety information from the generic drug's labeling.Specifically, the FDA may not deem an abbreviated application for approval of a generic drug ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's patent or exclusivity protections. Similarly, a drug that is approved under this bill may not be considered mislabeled for lacking such safety information.Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug (i.e., a generic drug). Currently, the labeling for such a generic drug must generally be identical to that of the already-approved drug. This bill provides an exception to that requirement under the specified circumstances. For any drug approved under this bill, the FDA must require the drug's labeling to include any safety information that is necessary to assure safe use.
Latest Action
Referred to the House Committee on Energy and Commerce.